Embed Size (px)
Citation preview
HCM/CPR/09/43508/1 – September 20091
Joint Working- Why, When and How?
Graham FranklinRegional Business Director, GlaxoSmithKlineXXX 10th November 2009
HCM/CPR/09/43508/1 – September 2009
The evolving environment
Ministerial Industry Strategy Group Partnership Working
Group
‘There are a number of areas where increased dialogue and partnership between the NHS
and industry would deliver significant benefits for
Governments, patients, industry and research’
Feb 08 March 08
March 09June 08
HCM/CPR/09/43508/1 – September 2009
NHS-ABPI defined Joint Working
Defined as situations where, for the benefit of patients, one or more pharmaceutical companies and the NHS pool skills, experience and/or resources for the joint development and implementation of patient-centered projects and share a commitment to successful delivery
HCM/CPR/09/43508/1 – September 2009
How can the NHS and the Pharmaceutical Industry find the mutual benefits of Joint Working?
Additional resources
Communication and IT expertise
Business planning skills
Appropriate use of medicines
Better customer understanding
Improved reputation and trust
Different perspectives Different perspectives
Creative approaches to problems Creative approaches to problems
Skilled personnel Skilled personnel
Better cross-sectoral working Better cross-sectoral working
Faster NHS implementation of policy Faster NHS implementation of policy
Better patient outcomes
The Pharmaceutical Industry
HCM/CPR/09/43508/1 – September 2009
What could a Joint Working Project Look Like?
Pooled resource– Mutual contribution to providing the resources to meet and
address the patient need:
• Staff training • Staff and or patient education• Economic analysis• Facilitation of pathway redesign• Support for guideline implementation • Funding of project staff requirements
(administrative, clinical, analytical health economic and or management resources)
HCM/CPR/09/43508/1 – September 2009
Examples of Partnership Working
HCM/CPR/09/43508/1 – September 2009
Improving COPD ManagementNHS Salford and GSK
NHS Salford
Project
Win/Win/Win
Results
Serves more than 216,000 patients
High COPD prevalence (2.5% vs 1.4% national average)
To enhance the group’s capability and capacity to appropriately manage its COPD patient population by implementing:
– Treatment pathways and protocol– Health Care Professional and patient education programmes– Patient audit tools (POINTS)– Patient review
Patient: Better outcomes via proactive treatment
NHS: Up-skilled staff, improving quality and resource utilisation
GSK: More opportunities for appropriate use of medicines
Analysis ongoing – interim data indicates:– Length of hospital stay reduced from 7.4 to 6.9 days1
– PCT hospital expenditure reduced by £167,0001
– An estimated 255 hospital admissions were avoided1
– 430 additional patients were added to the COPD register2
1. Data supplied by NHS Salford, 8 June 20092. Roberts JA and Diar Bakerly N Benchmarking COPD across an inner city PCT: one year on. Thorax (2008) (Suppl VII): A8 s12
HCM/MTP/09/43726/1, October 2009
HCM/CPR/09/43508/1 – September 2009
Exploring partnership opportunities further
GSK contact:– [email protected] – Regional Business Director
– [email protected] – Area Business Manager
– Visit the GSK Stand at London Health ’09
You can access the Joint Working Toolkit produced by the DH and ABPI on: www.dh.gov.uk
HCM/CPR/09/43508/1 – September 20099
Joint Working- Why, When and How?
Graham FranklinRegional Business Director, GlaxoSmithKlineXXX 10th November 2009
